Imfinzi granted breakthrough therapy designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer
Fourth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine in three years.
Fourth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine in three years.